Cargando…

The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy

PURPOSE: To evaluate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in predicting early treatment response. MATERIALS AND METHODS: Patients with locally advanced cervical cancer (LACC) treated with concurrent chemoradiotherapy (CCRT) were enrolled. Pelvic DCE-MRI scans we...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Heming, Wu, Yuying, Liu, Xu, Huang, Huixian, Jiang, Hailan, Zhu, Chaohua, Man, Yuping, Liu, Pei, Li, Xianglong, Chen, Zhaohong, Long, Xianfeng, Pang, Qiang, Deng, Shan, Gu, Junzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349537/
https://www.ncbi.nlm.nih.gov/pubmed/34377025
http://dx.doi.org/10.2147/CMAR.S314289
_version_ 1783735583844073472
author Lu, Heming
Wu, Yuying
Liu, Xu
Huang, Huixian
Jiang, Hailan
Zhu, Chaohua
Man, Yuping
Liu, Pei
Li, Xianglong
Chen, Zhaohong
Long, Xianfeng
Pang, Qiang
Deng, Shan
Gu, Junzhao
author_facet Lu, Heming
Wu, Yuying
Liu, Xu
Huang, Huixian
Jiang, Hailan
Zhu, Chaohua
Man, Yuping
Liu, Pei
Li, Xianglong
Chen, Zhaohong
Long, Xianfeng
Pang, Qiang
Deng, Shan
Gu, Junzhao
author_sort Lu, Heming
collection PubMed
description PURPOSE: To evaluate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in predicting early treatment response. MATERIALS AND METHODS: Patients with locally advanced cervical cancer (LACC) treated with concurrent chemoradiotherapy (CCRT) were enrolled. Pelvic DCE-MRI scans were performed before RT (pre-RT), in the middle of RT (mid-RT), and at the end of RT (post-RT), separately. Parameters (ie, K(trans), K(ep), and V(e)) were measured. Pre-, mid-, and post-RT K(trans) were denoted as K(trans)-preTx, K(trans)-midTx, and K(trans)-postTx, respectively. And the same denoting rule also went for K(ep) and V(e). Difference for the same parameter such as K(trans) measured between two consecutive time points was calculated as second K(trans) value minus first K(trans) value. The differences in K(trans) between pre-RT and post-RT, between pre-RT and mid-RT, and between mid-RT and post-RT were denoted as ΔK(trans)-post-preTx, ΔK(trans)-mid-preTx, and ΔK(trans)-post-midTx, respectively, and the same denoting rule was also applied to K(ep) and V(e). RESULTS: A total of 57 patients were enrolled. After the treatment, 31 patients had complete response (CR group). The remaining 26 patients had partial response (NCR group). Significant differences were found in K(trans)-postTx, K(ep-)postTx, V(e-)midTx, ΔK(trans)-post-preTx, ΔK(trans)-post-midTx, ΔK(ep-)post-preTx, ΔK(ep-)mid-preTx and ΔK(ep-)post-midTx between the two groups. Receiver operating characteristic (ROC) analysis for their performances in predicting treatment response showed an area under curve (AUC) of 0.656–0.849, sensitivity of 61.3–93.5%, specificity of 46.1–73.1%, and maximal Youden Index of 36.5–66.6. Among those parameters, K(ep-)postTx was the best, and its AUC, sensitivity, specificity, maximal Youden Index, and cutoff value were 0.849, 87.1%, 73.1%, 60.2, and 0.341, respectively. These combined parameters showed an AUC of 0.952, with sensitivity of 87.1%, specificity of 96.1%, and maximal Youden Index of 83.2. CONCLUSION: DCE-MRI parameters can predict early treatment outcome. Among those parameters, K(ep-)postTx is the best predictor. The combination of multi-parameters can increase the predictive potency.
format Online
Article
Text
id pubmed-8349537
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83495372021-08-09 The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy Lu, Heming Wu, Yuying Liu, Xu Huang, Huixian Jiang, Hailan Zhu, Chaohua Man, Yuping Liu, Pei Li, Xianglong Chen, Zhaohong Long, Xianfeng Pang, Qiang Deng, Shan Gu, Junzhao Cancer Manag Res Original Research PURPOSE: To evaluate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in predicting early treatment response. MATERIALS AND METHODS: Patients with locally advanced cervical cancer (LACC) treated with concurrent chemoradiotherapy (CCRT) were enrolled. Pelvic DCE-MRI scans were performed before RT (pre-RT), in the middle of RT (mid-RT), and at the end of RT (post-RT), separately. Parameters (ie, K(trans), K(ep), and V(e)) were measured. Pre-, mid-, and post-RT K(trans) were denoted as K(trans)-preTx, K(trans)-midTx, and K(trans)-postTx, respectively. And the same denoting rule also went for K(ep) and V(e). Difference for the same parameter such as K(trans) measured between two consecutive time points was calculated as second K(trans) value minus first K(trans) value. The differences in K(trans) between pre-RT and post-RT, between pre-RT and mid-RT, and between mid-RT and post-RT were denoted as ΔK(trans)-post-preTx, ΔK(trans)-mid-preTx, and ΔK(trans)-post-midTx, respectively, and the same denoting rule was also applied to K(ep) and V(e). RESULTS: A total of 57 patients were enrolled. After the treatment, 31 patients had complete response (CR group). The remaining 26 patients had partial response (NCR group). Significant differences were found in K(trans)-postTx, K(ep-)postTx, V(e-)midTx, ΔK(trans)-post-preTx, ΔK(trans)-post-midTx, ΔK(ep-)post-preTx, ΔK(ep-)mid-preTx and ΔK(ep-)post-midTx between the two groups. Receiver operating characteristic (ROC) analysis for their performances in predicting treatment response showed an area under curve (AUC) of 0.656–0.849, sensitivity of 61.3–93.5%, specificity of 46.1–73.1%, and maximal Youden Index of 36.5–66.6. Among those parameters, K(ep-)postTx was the best, and its AUC, sensitivity, specificity, maximal Youden Index, and cutoff value were 0.849, 87.1%, 73.1%, 60.2, and 0.341, respectively. These combined parameters showed an AUC of 0.952, with sensitivity of 87.1%, specificity of 96.1%, and maximal Youden Index of 83.2. CONCLUSION: DCE-MRI parameters can predict early treatment outcome. Among those parameters, K(ep-)postTx is the best predictor. The combination of multi-parameters can increase the predictive potency. Dove 2021-08-04 /pmc/articles/PMC8349537/ /pubmed/34377025 http://dx.doi.org/10.2147/CMAR.S314289 Text en © 2021 Lu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lu, Heming
Wu, Yuying
Liu, Xu
Huang, Huixian
Jiang, Hailan
Zhu, Chaohua
Man, Yuping
Liu, Pei
Li, Xianglong
Chen, Zhaohong
Long, Xianfeng
Pang, Qiang
Deng, Shan
Gu, Junzhao
The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy
title The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy
title_full The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy
title_fullStr The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy
title_full_unstemmed The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy
title_short The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy
title_sort role of dynamic contrast-enhanced magnetic resonance imaging in predicting treatment response for cervical cancer treated with concurrent chemoradiotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349537/
https://www.ncbi.nlm.nih.gov/pubmed/34377025
http://dx.doi.org/10.2147/CMAR.S314289
work_keys_str_mv AT luheming theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT wuyuying theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT liuxu theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT huanghuixian theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT jianghailan theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT zhuchaohua theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT manyuping theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT liupei theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT lixianglong theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT chenzhaohong theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT longxianfeng theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT pangqiang theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT dengshan theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT gujunzhao theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT luheming roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT wuyuying roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT liuxu roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT huanghuixian roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT jianghailan roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT zhuchaohua roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT manyuping roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT liupei roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT lixianglong roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT chenzhaohong roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT longxianfeng roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT pangqiang roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT dengshan roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy
AT gujunzhao roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy